These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22015691)

  • 1. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer.
    Janakiram NB; Mohammed A; Rao CV
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):507-23. PubMed ID: 22015691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer.
    Janakiram NB; Rao CV
    Curr Mol Med; 2009 Jun; 9(5):565-79. PubMed ID: 19601807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoxins and new lipid mediators in the resolution of inflammation.
    Schwab JM; Serhan CN
    Curr Opin Pharmacol; 2006 Aug; 6(4):414-20. PubMed ID: 16750421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomics.
    Serhan CN; Chiang N
    Rheum Dis Clin North Am; 2004 Feb; 30(1):69-95. PubMed ID: 15061569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel omega -- 3-derived local mediators in anti-inflammation and resolution.
    Serhan CN
    Pharmacol Ther; 2005 Jan; 105(1):7-21. PubMed ID: 15626453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases.
    Yacoubian S; Serhan CN
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):570-9; quiz 1 p following 589. PubMed ID: 17906612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators.
    Serhan CN
    J Periodontol; 2008 Aug; 79(8 Suppl):1520-6. PubMed ID: 18673006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution.
    Serhan CN
    Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):141-62. PubMed ID: 16005201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins.
    Hersberger M
    Clin Chem Lab Med; 2010 Aug; 48(8):1063-73. PubMed ID: 20441482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.
    Serhan CN
    Annu Rev Immunol; 2007; 25():101-37. PubMed ID: 17090225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The two faces of the 15-lipoxygenase in atherosclerosis.
    Wittwer J; Hersberger M
    Prostaglandins Leukot Essent Fatty Acids; 2007 Aug; 77(2):67-77. PubMed ID: 17869078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoxins: regulators of resolution.
    Ryan A; Godson C
    Curr Opin Pharmacol; 2010 Apr; 10(2):166-72. PubMed ID: 20226737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of inflammatory cytokines by omega-3 fatty acids.
    Kang JX; Weylandt KH
    Subcell Biochem; 2008; 49():133-43. PubMed ID: 18751910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipoxins--new view on old mediators carrying potent anti-inflammatory action].
    Jarmakowska K; Kuna P
    Pol Merkur Lekarski; 2005 May; 18(107):491-5. PubMed ID: 16161940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease.
    Massaro M; Scoditti E; Carluccio MA; De Caterina R
    Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):109-15. PubMed ID: 18951002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of inflammation in cancer by eicosanoids.
    Greene ER; Huang S; Serhan CN; Panigrahy D
    Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):27-36. PubMed ID: 21864702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions.
    Serhan CN; Clish CB; Brannon J; Colgan SP; Gronert K; Chiang N
    J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):643-54. PubMed ID: 11192938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primers on molecular pathways - lipoxygenases: their role as an oncogenic pathway in pancreatic cancer.
    Comba A; Pasqualini ME
    Pancreatology; 2009; 9(6):724-8. PubMed ID: 20016244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What the surgeon needs to know about basic new concepts of inflammation and their therapeutic consequences: sanitation of inflammation is not a passive but rather an active process regulated by lipid mediators].
    Gardemann A; Meyer F; Braun-Dullaeus R
    Zentralbl Chir; 2013 Jun; 138(3):322-30. PubMed ID: 23807584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pharmaceutical insights related to the pathways of PUFAs.
    Oblozinský M; Pekárová M; Hoffman P; Bezáková L
    Ceska Slov Farm; 2012 Aug; 61(4):139-43. PubMed ID: 23251954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.